Indaptus Q1 2025: cash burn $5.0M; $3.9M cash; needs capital beyond Q2 2025; Decoy20 combo trial started

Indaptus Therapeutics, Inc.

2025-Q1 EPS reported -$0.32 vs consensus -$5.14 ▲ beat (+93.8%)

Cash and equivalents $3.9M at March 31, 2025, down from $5.8M at Dec 31, 2024; Company needs additional capital beyond Q2 2025.
Net loss per share $0.32 in Q1 2025 vs $0.45 in Q1 2024; R&D expenses $2.8M (up from $1.6M) due to Phase 1 trial costs.
Initiated Phase 1b/2 combination arm of Decoy20 with BeOne's PD-1 inhibitor Tislelizumab; weekly dosing arm concluded after 32 patients.
Patents granted in China, Japan, Israel for Decoy platform; cost-reduction plan implemented to focus on combination study.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.